Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus

Summary

Megakaryocyte (MK)-derived miRNAs have been detected in platelets. Here, we analysed the expression of platelet and circulating miR-223, miR-26b, miR-126 and miR-140 that might be altered with their target mRNAs in type 2 diabetes mellitus (DM2). MiRNAs were isolated from leukocyte-depleted platelets and plasma samples obtained from 28 obese DM2, 19 non-DM obese and 23 healthy individuals. The effect of hyperglycaemia on miRNAs was also evaluated in MKs using MEG-01 and K562 cells under hyperglycaemic conditions after 8 hours up to four weeks. Quantitation of mature miRNA, pre-miRNAs and target mRNA levels (P2RY12 and SELP) were measured by RT-qPCR. To prove the association of miR-26b and miR-140 with SELP (P-selectin) mRNA level, overexpression or inhibition of these miRNAs in MEG-01 MKs was performed using mimics or anti-miRNAs, respectively. The contribution of calpain substrate Dicer to modulation of miRNAs was studied by calpain inhibition. Platelet activation was evaluated via surface P-selectin by flow cytometry. Mature and pre-forms of investigated miRNAs were significantly reduced in DM2, and platelet P2RY12 and SELP mRNA levels were elevated by two-fold at increased platelet activation compared to controls. Significantly blunted miRNA expressions were observed by hyperglycaemia in MEG-01 and K562-MK cells versus baseline values, while the manipulation of miR-26b and miR-140 expression affected SELP mRNA level. Calpeptin pretreatment restored miRNA levels in hyperglycaemic MKs. Overall, miR-223, miR-26b, miR-126 and miR-140 are expressed at a lower level in platelets and MKs in DM2 causing upregulation of P2RY12 and SELP mRNAs that may contribute to adverse platelet function.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Platelet activation - microRNA - megakaryocyte - diabetes mellitus - hyperglycaemia

• References

• 1 Ferroni P, Basili S, Falco A. et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 02: 1282-1291.
• 2 Nagy Jr B, Csongrádi E, Bhattoa HP. et al. Investigation of Thr715Pro P-selectin gene polymorphism and soluble P-selectin levels in type 2 diabetes mellitus. Thromb Haemost 2007; 98: 186-191.
• 3 Khaw KT, Wareham N, Bingham S. et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
• 4 Lemkes BA, Hermanides J, Devries JH. et al. Hyperglycaemia: a prothrombotic factor?. J Thromb Haemost 2010; 08: 1663-1669.
• 5 Yngen M, Ostenson CG, Li N. et al. Acute hyperglycaemia increases soluble P-selectin in male patients with mild diabetes mellitus. Blood Coagul Fibrinolysis 2001; 12: 109-116.
• 6 Holman RR, Paul SK, Bethel MA. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
• 7 Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21: 152-160.
• 8 Fadini GP, Ferraro F, Quaini F. et al. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl Med 2014; 03: 949-957.
• 9 Olivieri F, Bonafè M, Spazzafumo L. et al. Age- and glycaemia-related miR-126-3p levels in plasma and endothelial cells. Aging 2014; 06: 771-787.
• 10 Landry P, Plante I, Ouellet DL. et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16: 961-966.
• 11 Rondina MT, Weyrich AS. Regulation of the genetic code in megakaryocytes and platelets. J Thromb Haemost 2015; 13 (Suppl. 01) S26-32.
• 12 Pan Y, Liang H, Liu H. et al. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J Immunol 2014; 192: 437-446.
• 13 Teruel-Montoya R, Kong X, Abraham S. et al. MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression. PLoS One 2014; 09: e102259.
• 14 Nagalla S, Shaw C, Kong X. et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011; 117: 5189-5197.
• 15 Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008; 28: s17-24.
• 16 Liverani E, Kilpatrick LE, Tsygankov AY. et al. The role of P2Y12 receptor and activated platelets during inflammation. Curr Drug Targets 2014; 15: 720-728.
• 17 Matsuno H, Tokuda H, Ishisaki A. et al. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 2005; 90: 920-927.
• 18 Sudic D, Razmara M, Forslund M. et al. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006; 133: 315-322.
• 19 Nagy Jr B, Jin J, Ashby B. et al. Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolaemia. J Thromb Haemost 2011; 09: 810-819.
• 20 Kondkar AA, Bray MS, Leal SM. et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 08: 369-378.
• 21 Duan X, Zhan Q, Song B. et al. Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. J Diabetes Complications 2014; 28: 705-710.
• 22 Elgheznawy A, Shi L, Hu J. et al. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 2015; 117: 157-165.
• 23 Stenberg PE, McEver RP, Shuman MA. et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886.
• 24 Kappelmayer J, Nagy Jr B, Miszti-Blasius K. et al. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004; 42: 475-486.
• 25 Plé H, Landry P, Benham A. et al. The repertoire and features of human platelet microRNAs. PLoS One 2012; 07: e50746.
• 26 Czimmerer Z, Hulvely J, Simandi Z. et al. A versatile method to design stem-loop primer-based quantitative PCR assays for detecting small regulatory RNA molecules. PLoS One 2013; 08: e55168.
• 27 Westerweel PE, Teraa M, Rafii S. et al. Impaired endothelial progenitor cell mobilisation and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One 2013; 08: e60357.
• 28 Duncan MT, Shin S, Wu JJ. et al. Dynamic transcription factor activity profiles reveal key regulatory interactions during megakaryocytic and erythroid differentiation. Biotechnol Bioeng 2014; 111: 2082-2094.
• 29 Dobiásová M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem 2004; 50: 1113-1115.
• 30 Csongrádi É, Nagy Jr B, Fülöp T. et al. Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. Thromb Haemost 2011; 106: 683-692.
• 31 Stratz C, Nührenberg TG, Binder H. et al. Micro-array profiling exhibits remarkable intra-individual stability of human platelet micro-RNA. Thromb Haemost 2012; 107: 634-641.
• 32 Zampetaki A, Kiechl S, Drozdov I. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
• 33 Kaudewitz D, Skroblin P, Bender LH. et al. Association of MicroRNAs and YRNAs With Platelet Function. Circ Res 2016; 118: 420-432.
• 34 Zampetaki A, Willeit P, Tilling L. et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-299.
• 35 Edelstein LC, McKenzie SE, Shaw C. et al. MicroRNAs in platelet production and activation. J Thromb Haemost 2013; 11 (Suppl. 01) 340-350.
• 36 Pescador N, Pérez-Barba M, Ibarra JM. et al. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One 2013; 08: e77251.
• 37 Leierseder S, Petzold T, Zhang L. et al. MiR-223 is dispensable for platelet production and function in mice. Thromb Haemost 2013; 110: 1207-1214.
• 38 Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009; 32: 525-527.
• 39 Simon LM, Edelstein LC, Nagalla S. et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 2014; 123: e37-45.
• 40 Willeit P, Zampetaki A, Dudek K. et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112: 595-600.
• 41 Stratz C, Nührenberg T, Fiebich BL. et al. Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from micro-array profiling in a cohort of 60 patients. Thromb Haemost 2014; 111: 902-911.
• 42 Wang L, Erling P, Bengtsson AA. et al. Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and clusterin in patients with systemic lupus erythematosus. J Thromb Haemost 2004; 02: 1436-1442.
• 43 Shi R, Zhou X, Ji WJ. et al. The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy. Biomed Res Int 2015; 2015: 981841.
• 44 Zhang YY, Zhou X, Ji WJ. et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis 2014; 38: 65-72.
• 45 Jones MR, Quinton LJ, Blahna MT. et al. Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nat Cell Biol 2009; 11: 1157-1163.
• 46 Káplár M, Kappelmayer J, Veszprémi A. et al. The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets 2001; 12: 419-422.
• 47 Ye EA, Steinle JJ. miR-146a Attenuates Inflammatory Pathways Mediated by TLR4/NF-?B and TNFa to Protect Primary Human Retinal Microvascular Endothelial Cells Grown in High Glucose. Mediators Inflamm 2016; 2016: 3958453.
• 48 Xiang Y, Cheng J, Wang D. et al. Hyperglycaemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015; 125: 3377-3387.
• 49 Finn NA, Eapen D, Manocha P. et al. Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport. FEBS Lett 2013; 587: 3456-3463.
• 50 Randriamboavonjy V, Isaak J, Elgheznawy A. et al. Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. Blood 2012; 120: 415-423.